All information on this website is intended strictly for educational and research purposes only.
The content on OpenPep — including peptide profiles, clinical trial summaries, dosing information, and reconstitution calculators — must not be used for:
OpenPep aggregates publicly available clinical trial data and research. We do not sell, distribute, or recommend any substances. All AI-generated summaries are interpretations of published research and may contain errors.
Tirzepatide (GIP/GLP-1 dual agonist)
For educational and research purposes only. Not medical advice.
Tirzepatide has the strongest clinical evidence of any weight loss peptide, with Phase III SURMOUNT trials showing up to 22.5% body weight reduction. FDA-approved as Mounjaro (diabetes) and Zepbound (obesity). Gold-standard evidence with multiple large RCTs.
Best Time
Any time, same day each week
Method
subcutaneous
Frequency
Once weekly
Half-life
~5 days
Cycle Length
Ongoing (per prescription)
Storage
Refrigerate pen at 2-8°C. Can be at room temp for up to 21 days.
Published Dosing Ranges
Create an account to access peptide research data.
Contraindications
Create an account to access peptide research data.
Do NOT combine GLP-1 agonists. Overlapping receptor activation increases risk of severe GI side effects (nausea, vomiting, pancreatitis) with no additional benefit.
documentedOverlapping GLP-1 and GIP receptor agonism. Retatrutide adds glucagon receptor activity. Combining dual/triple agonists risks severe GI distress, hypoglycemia, and unpredictable receptor dynamics.
documentedNew England Journal of Medicine · 2021-01-01
Journal of diabetes 17 (4) :e70082 · 2025-04-01
Diabetes, obesity & metabolism 28 (6) :5043-5057 · 2026-06-01
Obesity (Silver Spring, Md.) · 2026-04-05
European journal of preventive cardiology 33 (7) :1210-1217 · 2026-05-15
Mechanism of Action
Dual agonist of GIP and GLP-1 receptors. Enhances insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through central and peripheral mechanisms.
Reported by the community. These may not be supported by clinical evidence and are not medical recommendations.